Roy Decker MD/PhD

Associate Professor of Therapeutic Radiology and Assistant Professor of Surgery (Otolaryngology); Clinical Research Program Leader, Therapeutic Radiology, Yale Cancer Center

Specialties & Subspecialties

Cancer Center, Yale: Head and Neck Cancer Surgery Program | Thoracic Oncology Program

Therapeutic Radiology/Radiation Oncology

Surgery

Radiation Oncology

Education & Training

  • B.A., University of Virginia (1988)
  • M.D./Ph.D., Medical College of Virginia, Richmond, Virginia (2002)
  • Resident, Yale-New Haven Hospital , Radiation Oncology  (2003 - 2007)
  • Intern, Medical College of Virginia Hospital , Internal Medicine 

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Head & Neck Cancer; Lung Cancer; Stereotactic Body Radiosurgery


Cancers Treated

Brachytherapy, Head & Neck, Lung, Prostate, Stereotactic Radiosurgery


Board Certifications

  • Therapeutic Radiology, Board Certified (2008)

Clinical Trials

Conditions Study Title
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and Pharynx A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer (RTOG 0920) {CIRB}
Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (RTOG 1216) {CIRB}
Brain and Nervous System and Other Respiratory and Intrathoracic Organs A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
Lung LCCC 1123: Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR Tyrosine Kinase Inhibitor (TKI)
Rectum KD018: Pilot Trial of KD018 with Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients with Locally Advanced Rectal Cancer

Edit Profile